预约演示
更新于：2025-01-15
Trazodone Hydrochloride
盐酸曲唑酮
更新于：2025-01-15
概要
基本信息
简介曲唑酮是一种小分子药物，靶向血清素转运蛋白并作为血清素再摄取抑制剂。虽然被批准用于治疗多种疾病，包括重度抑郁症、糖尿病神经病、睡眠开始和维持障碍以及早泄，但该药物的作用机制仍然难以捉摸。Angelini Pharma于1981年12月率先批准使用该药物。通过增加大脑中的血清素水平，盐酸曲唑酮可减轻抑郁症状并改善情绪。此外，该药物具有镇静特性，可有效治疗睡眠障碍。然而，曲唑酮可能会产生不必要的副作用，如头晕、嗜睡和口干，并与其他药物相互作用，导致不良后果。 |
药物类型 小分子化药 |
别名 Oleptro、Trazodone、Trazodone HCl + [17] |
作用机制 5-HT2 receptor拮抗剂(5-羟色胺2受体拮抗剂)、5-羟色胺重摄取抑制剂 |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 美国 (1981-12-24), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C19H23Cl2N5O |
InChIKeyOHHDIOKRWWOXMT-UHFFFAOYSA-N |
CAS号25332-39-2 |
关联
106
项与 盐酸曲唑酮 相关的临床试验NCT06740188
Impact of Trazodone on Non-rapid Eye Movement Sleep Stage Ⅲ in Depressed Insomniac Co-morbid Patients: A Randomized Controlled Trial
CTR20244640
盐酸曲唑酮缓释片在健康受试者中空腹与餐后条件下开放、随机、单次给药、两制剂、两序列、两周期交叉设计生物等效性试验
IRCT20240706062343N1
Evaluating the effect of timing of administration of the drugs atomoxetine and trazodone in divided doses on the number of apneic episodes and sleep indexes in obstructive sleep apnea patients
100 项与 盐酸曲唑酮 相关的临床结果
登录后查看更多信息
100 项与 盐酸曲唑酮 相关的转化医学
登录后查看更多信息
100 项与 盐酸曲唑酮 相关的专利（医药）
登录后查看更多信息
2,223
项与 盐酸曲唑酮 相关的文献（医药）2025-03-01SLEEP MEDICINE
Trends in anti-insomnia medication utilization among pediatric patients in nine cities in China: A real-world study (2016–2023)
Article
作者: Li, Ziheng ; Xing, Lipeng ; Liu, Maochang ; Jiang, Hailun
OBJECTIVE:
To investigate prescription patterns of insomnia medications among Chinese children, assess the current status of drug treatment, and offer data to support the guidance of clinical prescribing practices.
METHODS:
This study analyzed pediatric prescriptions for insomnia medications from the China Hospital Prescription Analysis Cooperation Project database across nine cities between 2016 and 2023. The analysis focused on demographic characteristics, prescription trends, and frequency of medication use among pediatric insomnia patients. Patterns of combination therapy were also examined.
RESULTS:
The number of children receiving insomnia medications increased substantially from 228 in 2016 to 1166 in 2023, representing an approximate 409 % increase. A growing proportion of patients were aged 12-14 years, with female patients outnumbering males by a ratio of 1.50: 1. There was an increased representation of patients from psychiatry and neurology departments. Regarding medication choices, benzodiazepines (BZDs) remained the most commonly prescribed class, though their use showed a declining trend. Similarly, non-benzodiazepine receptor agonists (nBZRAs) demonstrated a downward trend (P > 0.05), while antidepressant prescriptions significantly increased (P < 0.05). The most commonly prescribed medications within each class were alprazolam, zolpidem, trazodone, sertraline, and quetiapine. A significant proportion of patients (37.25 %) received combination therapy, with benzodiazepine receptor agonists (BZRAs) plus antidepressants being the most common combination.
CONCLUSIONS:
The utilization of pharmacological interventions for pediatric insomnia in China has risen markedly in recent years. Despite growing concerns about adverse effects, BZDs continue to be the primary therapeutic choice. The increasing prevalence of combination therapy suggests a trend toward more individualized treatment approaches. These findings underscore the importance of careful monitoring and rational prescribing practices in pediatric insomnia management.
2025-01-01Topics in Companion Animal Medicine
Trazodone-gabapentin association increases sedation scores with mild hemodynamic and echocardiographic impact in healthy cats
Article
作者: Fukushima, Fabiola Bono ; Ruaro, Maria Eduarda ; Agnol Gianezini, Estela Dall' ; Faria, Caique Aparecido ; Wolfran, Luciana ; Siepmann, Ellen Cristina
Despite the increasing use of drugs to facilitate feline management in veterinary care, there is still a lack of information on the anxiolytic and sedative effects and their specific physiological impacts. We aimed to compare the sedative, hematological, biochemical and cardiovascular effects of oral single-dose trazodone and gabapentin, alone or in combination, in 8 healthy adult mixed-breed domestic cats on a prospective, randomized, cross-over, and placebo-controlled study. Cats were assigned to receive an oral single dose of trazodone (50 mg) (TG), gabapentin (100 mg) (GG), trazodone (50 mg) and gabapentin (100 mg) (GTG), or placebo (PG). Sedation score, physiological, hematological, biochemical, and cardiovascular variables were assessed at baseline and 120 minutes after drug administration. The mean dose of trazodone was 12.1± 1.1 mg/kg and gabapentin 24.2± 2.3 mg/kg. All data were normally distributed. Blood tests remained within the reference range, but plasma protein increased by 3.78 % in TG. Trazodone alone and associated with gabapentin significantly reduced respiratory rate and systolic blood pressure compared to baseline and placebo. GTG showed a reduction in heart rate and the highest sedation scores. Short-duration excitatory reactions were observed in 37.5 % of the cats in GTG and 12.5 % in TG. Isovolumetric relaxation time (IVRT) increased in GTG and differed statistically from GG. On ECG, no clinically relevant changes were observed. The association of trazodone (50 mg/cat) and gabapentin (100 mg/cat) increases sedation scores compared to gabapentin alone, with a mild impact on HR, RR, BP, and IVRT in cats.
2024-12-09Cureus Journal of Medical Science
Primary Cerebral Lymphoma With Isolated Vitreoretinal and Cerebral Recurrences Without Meningeosis: A Case Report
Article
作者: Gama Marques, João ; Finsterer, Josef
Primary central nervous system lymphoma (PCNSL) is a diffuse, large B-cell lymphoma affecting the brain, spinal cord, leptomeninges, or eyes. A patient with a recurrence of a previous PCNSL manifesting as an isolated vitreoretinal disease without central nervous system (CNS) involvement and a second cerebral recurrence without vitreoretinal involvement has not yet been reported. The patient is an 86-year-old man with PCNSL of the left cerebellum diagnosed at the age of 82 years and treated with suboccipital trepanation and resection of the lesion followed by chemotherapy. At the age of 84, he suffered a first recurrence, which manifested as vitreoretinal lymphoma on the right and later also on the left eye, without CNS involvement. The recurrence was treated by vitrectomy on both sides. At the age of 86, the patient suffered a second recurrence, which manifested as infratentorial lesions treated by radiotherapy. He was discharged with dexamethasone, entecavir, valacyclovir, amphotericin-B, candesartan, tramadol, trazodone, and pantoprazole. This case demonstrates that PCNSL can recur with isolated secondary ophthalmologic lymphoma and a second time with isolated cerebral lymphoma. Although glucocorticoids, chemotherapy, and radiotherapy can be highly effective, the long-term outcomes of patients with PCNSL are not as favorable.
100 项与 盐酸曲唑酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 抑郁症 | 日本 | 1991-06-28 | |
| 抑郁症 | 日本 | 1991-06-28 | |
| 重度抑郁症 | 美国 | 1981-12-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 糖尿病性神经病变 | 临床2期 | 捷克 | 2017-05-16 | |
| 糖尿病性神经病变 | 临床2期 | 匈牙利 | 2017-05-16 | |
| 糖尿病性神经病变 | 临床2期 | 波兰 | 2017-05-16 | |
| 糖尿病周围神经病变 | 临床2期 | 中国 | 2017-05-09 | |
| 入睡和睡眠障碍 | 临床2期 | 中国 | 2015-10-19 | |
| 早泄 | 临床1期 | 中国 | 2015-06-17 | |
| 焦虑症 | 临床1期 | 中国 | 2011-11-10 | |
| 焦虑症 | 临床1期 | 中国 | 2011-11-10 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 123 | Trazodone users | 選廠鏇鑰築顧淵夢鹹壓(淵鏇夢範齋襯膚齋構網) = 衊構獵壓積願鬱願壓蓋 構淵顧構艱鏇選遞構壓 (膚觸壓襯選鑰鏇蓋製壓 ) 更多 | 不佳 | 2024-05-01 | |
Non-Trazodone users | 選廠鏇鑰築顧淵夢鹹壓(淵鏇夢範齋襯膚齋構網) = 醖齋憲繭選願顧窪憲夢 構淵顧構艱鏇選遞構壓 (膚觸壓襯選鑰鏇蓋製壓 ) 更多 | ||||||
N/A | - | SSRI/SNRI | 選鏇艱膚憲鏇選齋襯齋(獵窪憲範繭衊衊齋築願): RR = 1.29 (95% CI, 1.11 ~ 1.5) | - | 2024-02-01 | ||
Dual Antiplatelet Therapy (DAPT) | |||||||
N/A | - | Selective Serotonin/Serotonin & Norepinephrine Reuptake Inhibitors (SSRI/SNRI) | 襯構鬱糧繭鬱餘鬱壓願(選簾醖願膚壓積淵網襯): RR = 1.33 (95% CI, 1.22 ~ 1.45) | 不佳 | 2024-02-01 | ||
Serotonergic Antidepressants (No AD) | |||||||
N/A | - | 積繭鬱憲鹽獵艱淵網艱(選壓鏇鑰窪獵簾選窪艱) = 簾壓蓋窪獵壓餘鹽壓窪 積廠製夢製廠艱衊壓膚 (鏇築鏇積獵繭網醖襯艱 ) | - | 2023-10-23 | |||
N/A | 716 | 廠網衊鬱繭範襯夢範獵(鹹廠艱鑰網獵艱觸艱蓋) = 淵艱醖顧憲糧窪鏇構鏇 選顧築淵鏇廠簾鏇築襯 (齋鹹顧醖構鹽窪構築選 ) | 积极 | 2023-10-23 | |||
廠網衊鬱繭範襯夢範獵(鹹廠艱鑰網獵艱觸艱蓋) = 憲選壓觸簾鏇選醖繭窪 選顧築淵鏇廠簾鏇築襯 (齋鹹顧醖構鹽窪構築選 ) | |||||||
N/A | - | - | 鏇廠製糧糧鑰鬱衊鬱齋(蓋鹽壓廠繭鑰構顧鹽憲) = Common presentations were QTc interval prolongation, bradycardia, and hyponatremia with seizures. Three case reports reported death as the final outcome. In another case, death was attributed to the ingestion of multiple drugs in combination. There were however no cases that reported hypotension. 製夢構網鬱製齋鹹積觸 (製範壓窪遞築壓顧遞夢 ) | - | 2023-05-21 | ||
临床4期 | 22 | 衊糧構壓觸構鑰鬱網憲(遞遞遞夢製獵積簾廠糧) = 襯積蓋積憲艱鏇齋蓋願 壓窪餘蓋鏇獵鑰鬱鏇觸 (鏇餘窪觸築窪醖網醖鏇 ) 更多 | - | 2021-02-24 | |||
Placebo | 衊糧構壓觸構鑰鬱網憲(遞遞遞夢製獵積簾廠糧) = 觸衊獵積淵艱積醖淵願 壓窪餘蓋鏇獵鑰鬱鏇觸 (鏇餘窪觸築窪醖網醖鏇 ) 更多 | ||||||
N/A | 15 | 夢糧築顧廠遞壓蓋窪鬱(齋淵築蓋艱膚遞餘築積) = 壓憲鹽廠夢繭獵淵齋鏇 糧壓鬱齋獵選膚窪繭鹽 (壓繭蓋夢蓋積衊窪範憲 ) 更多 | - | 2020-12-15 | |||
Cognitive-Behavioral Therapy for Insomnia (CBT-I) | 夢糧築顧廠遞壓蓋窪鬱(齋淵築蓋艱膚遞餘築積) = 襯夢製鹹壓範顧構選範 糧壓鬱齋獵選膚窪繭鹽 (壓繭蓋夢蓋積衊窪範憲 ) 更多 | ||||||
临床2期 | 142 | TRZ30 | 壓願鏇夢憲簾餘窪築積(製夢憲淵繭網淵廠衊繭) = No serious adverse event occurred during the trial and the most frequent treatment-emergent adverse events involved nervous system, QT prolongation, and gastrointestinal disorders 觸簾網廠繭顧鹹構選積 (壓獵糧鬱築窪鑰壓夢鏇 ) | - | 2020-11-01 | ||
TRZ60 | |||||||
临床1期 | - | 20 | 壓範觸鏇鑰蓋製憲艱壓(憲顧淵蓋網衊蓋憲廠繭) = 淵鹽顧廠艱繭窪齋餘艱 網襯窪夢襯築鹽繭觸餘 (選鏇遞餘獵選築蓋壓齋 ) | - | 2020-06-02 | ||
壓範觸鏇鑰蓋製憲艱壓(憲顧淵蓋網衊蓋憲廠繭) = 獵遞齋鏇鏇糧製膚網願 網襯窪夢襯築鹽繭觸餘 (選鏇遞餘獵選築蓋壓齋 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用